I am very pleased to let you know that the International Quality Network for Pathology (IQN Path), the European Cancer Patient Coalition (ECPC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have recently published a joint report entitled “Unlocking the potential of precision medicine in Europe – Improving cancer care through broader access to quality biomarker testing”.
IQN Path, ECPC and EFPIA have assessed biomarkers’ access and quality across Europe (27 EU Member States and the UK) and generated a biomarker access and quality scorecard for each of these countries (copied below). The collected data have helped map the ideal pathway for the uptake and use of biomarkers and identify common gaps across countries.
Based on this analysis, IQN Path, ECPC and EFPIA have developed a set of policy recommendations aimed at improving the access to high quality tests for better outcomes for patients with cancer in Europe.
Please find the report available at the link below.
We have also developed a supportive infographic available at the link below and attached.
You can also have a look at the webinar presenting the results of the report available at the link below.
I also copy below the mapping that was developed highlighting the significant variations in medicines and test access as well as test quality across Europe.
Senior Manager Healthcare Systems and SMEs
EFPIA – European Federation of Pharmaceutical Industries and Associations